Design and synthesis of potent and selective inhibitors of BRD7 and BRD9 bromodomains

Duncan A. Hay, Catherine M. Rogers, Oleg Fedorov, Cynthia Tallant, Sarah Martin, Octovia P. Monteiro, Susanne Müller, Stefan Knapp, Christopher J. Schofield and Paul E. Brennan

Med. Chem. Commun., 2015, 6, 1381
DOI: 10.1039/C5MD00152H

Fragments in bromodomain drug discovery

Paul Bamborough and Chun-wa Chung

Med. Chem. Commun., 2015, 6, 1587
DOI: 10.1039/C5MD00209E

Targeting Brd4 for cancer therapy: inhibitors and degraders

Yingchao Duan, Yuanyuan Guan, Wenping Qin, Xiaoyu Zhai, Bin Yu and Hongmin Liu

Med. Chem. Commun., 2018, 9, 1779
DOI: 10.1039/C8MD00198G

Synthesis of C4-alkynylisoxazoles via a Pd-catalyzed Sonogashira cross-coupling reaction

Wen Yang, Yongqi Yao, Xin Yang, Yingying Deng, Qifu Lin and Dingqiao Yang

RSC Adv., 2019, 9, 8894
DOI: 10.1039/C9RA00577C

Insight into the key interactions of bromodomain inhibitors based on molecular docking, interaction fingerprinting, molecular dynamics and binding free energy calculation

Ting Ran, Zhimin Zhang, Kejun Liu, Yi Lu, Huifang Li, Jinxing Xu, Xiao Xiong, Yanmin Zhang, Anyang Xu, Shuai Lu, Haichun Liu, Tao Lu and Yadong Chen

Molecular BioSystems, 2015, 11, 1295
DOI: 10.1039/C4MB00723A

Direct photocapture of bromodomains using tropolone chemical probes

Erik C. Hett, Eugene L. Piatnitski Chekler, Arindrajit Basak, Paul D. Bonin, R. Aldrin Denny, Andrew C. Flick, Kieran F. Geoghegan, Shenping Liu, Mathew T. Pletcher, Parag Sahasrabudhe, Shores C. Salter, Ingrid A. Stock, Alexandria P. Taylor and Lyn H. Jones

Med. Chem. Commun., 2015, 6, 1018
DOI: 10.1039/C5MD00070J

Discovery of BET bromodomain inhibitors and their role in target validation

S. Müller and S. Knapp

Med. Chem. Commun., 2014, 5, 288
DOI: 10.1039/C3MD00291H

Chemogenomics for drug discovery: clinical molecules from open access chemical probes

Robert B. A. Quinlan and Paul E. Brennan

RSC Chem. Biol., 2021, 2, 759
DOI: 10.1039/D1CB00016K

Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer

Xiaoqian Xue, Yan Zhang, Chao Wang, Maofeng Zhang, Qiuping Xiang, Junjian Wang, Anhui Wang, Chenchang Li, Cheng Zhang, Lingjiao Zou, Rui Wang, Shuang Wu, Yongzhi Lu, Hongwu Chen, Ke Ding, Guohui Li and Yong Xu

European Journal of Medicinal Chemistry, 2018, 152, 542
DOI: 10.1016/j.ejmech.2018.04.034

BET Bromodomain Inhibitors with One-Step Synthesis Discovered from Virtual Screen

Alex M. Ayoub, Laura M. L. Hawk, Ryan J. Herzig, Jiewei Jiang, Andrea J. Wisniewski, Clifford T. Gee, Peiliang Zhao, Jin-Yi Zhu, Norbert Berndt, Nana K. Offei-Addo, Thomas G. Scott, Jun Qi, James E. Bradner, Timothy R. Ward, Ernst Schönbrunn, Gunda I. Georg and William C. K. Pomerantz

J. Med. Chem., 2017, 60, 4805
DOI: 10.1021/acs.jmedchem.6b01336

Bromodomains and Their Pharmacological Inhibitors

Daniel Gallenkamp, Kathy A. Gelato, Bernard Haendler and Hilmar Weinmann

ChemMedChem, 2014, 9, 438
DOI: 10.1002/cmdc.201300434

Discovery of Novel Small-Molecule Inhibitors of BRD4 Using Structure-Based Virtual Screening

Lewis R. Vidler, Panagis Filippakopoulos, Oleg Fedorov, Sarah Picaud, Sarah Martin, Michael Tomsett, Hannah Woodward, Nathan Brown, Stefan Knapp and Swen Hoelder

J. Med. Chem., 2013, 56, 8073
DOI: 10.1021/jm4011302

A Series of Potent CREBBP Bromodomain Ligands Reveals an Induced‐Fit Pocket Stabilized by a Cation–π Interaction

Timothy P. C. Rooney, Panagis Filippakopoulos, Oleg Fedorov, Sarah Picaud, Wilian A. Cortopassi, Duncan A. Hay, Sarah Martin, Anthony Tumber, Catherine M. Rogers, Martin Philpott, Minghua Wang, Amber L. Thompson, Tom D. Heightman, David C. Pryde, Andrew Cook, Robert S. Paton, Susanne Müller, Stefan Knapp, Paul E. Brennan and Stuart J. Conway

Angewandte Chemie, 2014, 126, 6240
DOI: 10.1002/ange.201402750

Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors

F. Anthony Romero, Alexander M. Taylor, Terry D. Crawford, Vickie Tsui, Alexandre Côté and Steven Magnuson

J. Med. Chem., 2016, 59, 1271
DOI: 10.1021/acs.jmedchem.5b01514

Structural, spectroscopic (FT-IR, FT-Raman, NMR) and computational analysis (DOS, NBO, Fukui) of 3,5-dimethylisoxazole and 4-(chloromethyl)-3,5-dimethylisoxazole: A DFT study

T. Kavitha and G. Velraj

J. Theor. Comput. Chem., 2016, 15, 1650039
DOI: 10.1142/S0219633616500395

Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation

Xiaoqian Xue, Yan Zhang, Zhaoxuan Liu, Ming Song, Yanli Xing, Qiuping Xiang, Zhen Wang, Zhengchao Tu, Yulai Zhou, Ke Ding and Yong Xu

J. Med. Chem., 2016, 59, 1565
DOI: 10.1021/acs.jmedchem.5b01511

Targeting BET Bromodomains for Cancer Treatment

Marie Jung, Kathy A Gelato, Amaury Fernández-Montalván, Stephan Siegel and Bernard Haendler

Epigenomics, 2015, 7, 487
DOI: 10.2217/epi.14.91

Synthetic and medicinal chemistry of phthalazines: Recent developments, opportunities and challenges

Sumera Zaib and Imtiaz Khan

Bioorganic Chemistry, 2020, 105, 104425
DOI: 10.1016/j.bioorg.2020.104425

Bioactivation of Isoxazole-Containing Bromodomain and Extra-Terminal Domain (BET) Inhibitors

Noah R. Flynn, Michael D. Ward, Mary A. Schleiff, Corentine M. C. Laurin, Rohit Farmer, Stuart J. Conway, Gunnar Boysen, S. Joshua Swamidass and Grover P. Miller

Metabolites, 2021, 11, 390
DOI: 10.3390/metabo11060390

Recent Advances on Small-Molecule Bromodomain-Containing Histone Acetyltransferase Inhibitors

Mingxia Liu, Kaiyao Zhang, Qinjue Li, Haiying Pang, Zhaoping Pan, Xiaowei Huang, Lian Wang, Fengbo Wu and Gu He

J. Med. Chem., 2023, 66, 1678
DOI: 10.1021/acs.jmedchem.2c01638

Discovery of Chemical Inhibitors of Human Bromodomains

Guangtao Zhang, Steven G. Smith and Ming-Ming Zhou

Chem. Rev., 2015, 115, 11625
DOI: 10.1021/acs.chemrev.5b00205

Controlling Intramolecular Interactions in the Design of Selective, High-Affinity Ligands for the CREBBP Bromodomain

Michael Brand, James Clayton, Mustafa Moroglu, Matthias Schiedel, Sarah Picaud, Joseph P. Bluck, Anna Skwarska, Hannah Bolland, Anthony K. N. Chan, Corentine M. C. Laurin, Amy R. Scorah, Larissa See, Timothy P. C. Rooney, Katrina H. Andrews, Oleg Fedorov, Gabriella Perell, Prakriti Kalra, Kayla B. Vinh, Wilian A. Cortopassi, Pascal Heitel, Kirsten E. Christensen, Richard I. Cooper, Robert S. Paton, William C. K. Pomerantz, Philip C. Biggin, Ester M. Hammond, Panagis Filippakopoulos and Stuart J. Conway

J. Med. Chem., 2021, 64, 10102
DOI: 10.1021/acs.jmedchem.1c00348

Optimization of 3,5-Dimethylisoxazole Derivatives as Potent Bromodomain Ligands

David S. Hewings, Oleg Fedorov, Panagis Filippakopoulos, Sarah Martin, Sarah Picaud, Anthony Tumber, Christopher Wells, Monica M. Olcina, Katherine Freeman, Andrew Gill, Alison J. Ritchie, David W. Sheppard, Angela J. Russell, Ester M. Hammond, Stefan Knapp, Paul E. Brennan and Stuart J. Conway

J. Med. Chem., 2013, 56, 3217
DOI: 10.1021/jm301588r

Isoxazole‐Derived Amino Acids are Bromodomain‐Binding Acetyl‐Lysine Mimics: Incorporation into Histone H4 Peptides and Histone H3

Angelina R. Sekirnik (née Measures), David S. Hewings, Natalie H. Theodoulou, Lukass Jursins, Katie R. Lewendon, Laura E. Jennings, Timothy P. C. Rooney, Tom D. Heightman and Stuart J. Conway

Angew Chem Int Ed, 2016, 55, 8353
DOI: 10.1002/anie.201602908

Protein Lysine Acetylation by p300/CBP

Beverley M. Dancy and Philip A. Cole

Chem. Rev., 2015, 115, 2419
DOI: 10.1021/cr500452k

Fragment-based in silico screening of bromodomain ligands

Dimitrios Spiliotopoulos and Amedeo Caflisch

Drug Discovery Today: Technologies, 2016, 19, 81
DOI: 10.1016/j.ddtec.2016.06.003

Discovery of a potent, orally available tricyclic derivative as a novel BRD4 inhibitor for melanoma

Yuhei Horai, Naoki Suda, Shinsuke Uchihashi, Mayako Katakuse, Tomomi Shigeno, Takashige Hirano, Junichi Takahara, Tomoyuki Fujita, Yohei Mukoyama and Yuji Haga

Bioorganic & Medicinal Chemistry, 2023, 93, 117461
DOI: 10.1016/j.bmc.2023.117461

Chromatin Regulatory Targets for Anticancer Therapeutics

Paige A. Barta, Trever R. Carter and Michael A. Erb

Chem. Rev., 2025, 125, 9679
DOI: 10.1021/acs.chemrev.5c00231

Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors

Victor S. Gehling, Michael C. Hewitt, Rishi G. Vaswani, Yves Leblanc, Alexandre Côté, Christopher G. Nasveschuk, Alexander M. Taylor, Jean-Christophe Harmange, James E. Audia, Eneida Pardo, Shivangi Joshi, Peter Sandy, Jennifer A. Mertz, Robert J. Sims, Louise Bergeron, Barbara M. Bryant, Steve Bellon, Florence Poy, Hariharan Jayaram, Ravichandran Sankaranarayanan, Sreegouri Yellapantula, Nandana Bangalore Srinivasamurthy, Swarnakumari Birudukota and Brian K. Albrecht

ACS Med. Chem. Lett., 2013, 4, 835
DOI: 10.1021/ml4001485

Molecular Dynamics Simulations of Bromodomains Reveal Binding‐Site Flexibility and Multiple Binding Modes of the Natural Ligand Acetyl‐Lysine

Dimitrios Spiliotopoulos and Amedeo Caflisch

Israel Journal of Chemistry, 2014, 54, 1084
DOI: 10.1002/ijch.201400009

Design, synthesis and biological evaluation of dihydroquinoxalinone derivatives as BRD4 inhibitors

Yifei Yang, Leilei Zhao, Bin Xu, LingYun Yang, Jian Zhang, Huibin Zhang and Jinpei Zhou

Bioorganic Chemistry, 2016, 68, 236
DOI: 10.1016/j.bioorg.2016.08.009

CBP/p300 bromodomain: new promising epigenetic target

Qiuping Xiang, Yang Zhou, Yan Zhang and Yong Xu

Vis Cancer Med, 2022, 3, 3
DOI: 10.1051/vcm/2022004

Naphthyridines as Novel BET Family Bromodomain Inhibitors

Olivier Mirguet, Yann Lamotte, Chun‐wa Chung, Paul Bamborough, Delphine Delannée, Anne Bouillot, Françoise Gellibert, Gael Krysa, Antonia Lewis, Jason Witherington, Pascal Huet, Yann Dudit, Lionel Trottet and Edwige Nicodeme

ChemMedChem, 2014, 9, 580
DOI: 10.1002/cmdc.201300259

BET bromodomain proteins and epigenetic regulation of inflammation: implications for type 2 diabetes and breast cancer

Dequina A. Nicholas, Guillaume Andrieu, Katherine J. Strissel, Barbara S. Nikolajczyk and Gerald V. Denis

Cell. Mol. Life Sci., 2017, 74, 231
DOI: 10.1007/s00018-016-2320-0

Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor

David Sperandio, Vangelis Aktoudianakis, Kerim Babaoglu, Xiaowu Chen, Kristyna Elbel, Gregory Chin, Britton Corkey, Jinfa Du, Bob Jiang, Tetsuya Kobayashi, Richard Mackman, Ruben Martinez, Hai Yang, Jeff Zablocki, Saritha Kusam, Kim Jordan, Heather Webb, Jamie G. Bates, Latesh Lad, Michael Mish, Anita Niedziela-Majka, Sammy Metobo, Annapurna Sapre, Magdeleine Hung, Debi Jin, Wanchi Fung, Elaine Kan, Gene Eisenberg, Nate Larson, Zachary E.R. Newby, Eric Lansdon, Chin Tay, Richard M. Neve, Sophia L. Shevick and David G. Breckenridge

Bioorganic & Medicinal Chemistry, 2019, 27, 457
DOI: 10.1016/j.bmc.2018.11.020

Small Molecule Ligands of the BET-like Bromodomain, SmBRD3, Affect Schistosoma mansoni Survival, Oviposition, and Development

Matthias Schiedel, Darius J. B. McArdle, Gilda Padalino, Anthony K. N. Chan, Josephine Forde-Thomas, Michael McDonough, Helen Whiteland, Manfred Beckmann, Rosa Cookson, Karl F. Hoffmann and Stuart J. Conway

J. Med. Chem., 2023, 66, 15801
DOI: 10.1021/acs.jmedchem.3c01321

Structure-Based Design of Highly Selective Inhibitors of the CREB Binding Protein Bromodomain

R. Aldrin Denny, Andrew C. Flick, Jotham Coe, Jonathan Langille, Arindrajit Basak, Shenping Liu, Ingrid Stock, Parag Sahasrabudhe, Paul Bonin, Duncan A. Hay, Paul E. Brennan, Mathew Pletcher, Lyn H. Jones and Eugene L. Piatnitski Chekler

J. Med. Chem., 2017, 60, 5349
DOI: 10.1021/acs.jmedchem.6b01839

Recent Developments in the Synthesis and Reactivity of Isoxazoles: Metal Catalysis and Beyond

Feng Hu and Michal Szostak

Adv Synth Catal, 2015, 357, 2583
DOI: 10.1002/adsc.201500319

Discovery of CREBBP Bromodomain Inhibitors by High-Throughput Docking and Hit Optimization Guided by Molecular Dynamics

Min Xu, Andrea Unzue, Jing Dong, Dimitrios Spiliotopoulos, Cristina Nevado and Amedeo Caflisch

J. Med. Chem., 2016, 59, 1340
DOI: 10.1021/acs.jmedchem.5b00171

Pharmacophore‐based virtual screening, molecular docking, molecular dynamics simulation, and biological evaluation for the discovery of novel BRD4 inhibitors

Guoyi Yan, Manzhou Hou, Jiang Luo, Chunlan Pu, Xueyan Hou, Suke Lan and Rui Li

Chem Biol Drug Des, 2018, 91, 478
DOI: 10.1111/cbdd.13109

Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors

Xu Ran, Yujun Zhao, Liu Liu, Longchuan Bai, Chao-Yie Yang, Bing Zhou, Jennifer L. Meagher, Krishnapriya Chinnaswamy, Jeanne A. Stuckey and Shaomeng Wang

J. Med. Chem., 2015, 58, 4927
DOI: 10.1021/acs.jmedchem.5b00613

Small Molecule Inhibitors of Bromodomain–Acetyl-lysine Interactions

Michael Brand, Angelina M. Measures, Brian G. Wilson, Wilian A. Cortopassi, Rikki Alexander, Matthias Höss, David S. Hewings, Timothy P. C. Rooney, Robert S. Paton and Stuart J. Conway

ACS Chem. Biol., 2015, 10, 22
DOI: 10.1021/cb500996u

Isoxazole‐Derived Amino Acids are Bromodomain‐Binding Acetyl‐Lysine Mimics: Incorporation into Histone H4 Peptides and Histone H3

Angelina R. Sekirnik (née Measures), David S. Hewings, Natalie H. Theodoulou, Lukass Jursins, Katie R. Lewendon, Laura E. Jennings, Timothy P. C. Rooney, Tom D. Heightman and Stuart J. Conway

Angewandte Chemie, 2016, 128, 8493
DOI: 10.1002/ange.201602908

[1,2,4]Triazolo[4,3-a]phthalazines: Inhibitors of Diverse Bromodomains

Oleg Fedorov, Hannah Lingard, Chris Wells, Octovia P. Monteiro, Sarah Picaud, Tracy Keates, Clarence Yapp, Martin Philpott, Sarah J. Martin, Ildiko Felletar, Brian D. Marsden, Panagis Filippakopoulos, Susanne Müller, Stefan Knapp and Paul E. Brennan

J. Med. Chem., 2014, 57, 462
DOI: 10.1021/jm401568s

Pharmacology Profile of Recently Developed Multi‐Functional Azoles; SAR‐Based Predictive Structural Modification

Atukuri Dorababu

ChemistrySelect, 2020, 5, 6730
DOI: 10.1002/slct.202000294

Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734

Filippo Spriano, Eugenio Gaudio, Luciano Cascione, Chiara Tarantelli, Federica Melle, Giovanna Motta, Valdemar Priebe, Andrea Rinaldi, Gaetanina Golino, Afua Adjeiwaa Mensah, Luca Aresu, Emanuele Zucca, Stefano Pileri, Michael Witcher, Bill Brown, Claes Wahlestedt, Francis Giles, Anastasios Stathis and Francesco Bertoni

Blood Advances, 2020, 4, 4124
DOI: 10.1182/bloodadvances.2020001879

Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains

Duncan A. Hay, Oleg Fedorov, Sarah Martin, Dean C. Singleton, Cynthia Tallant, Christopher Wells, Sarah Picaud, Martin Philpott, Octovia P. Monteiro, Catherine M. Rogers, Stuart J. Conway, Timothy P. C. Rooney, Anthony Tumber, Clarence Yapp, Panagis Filippakopoulos, Mark E. Bunnage, Susanne Müller, Stefan Knapp, Christopher J. Schofield and Paul E. Brennan

J. Am. Chem. Soc., 2014, 136, 9308
DOI: 10.1021/ja412434f

H–bonded mesogenic unsymmetric bis-heterocycles

Gou-Wei Luo, Chien-Yu Hu, Zih-Yang Lei, Gene-Hsiang Lee and Chung K. Lai

Journal of Molecular Liquids, 2018, 261, 76
DOI: 10.1016/j.molliq.2018.03.095

Epigenetic drugs that do not target enzyme activity

Dafydd R. Owen and John D. Trzupek

Drug Discovery Today: Technologies, 2014, 12, e29
DOI: 10.1016/j.ddtec.2012.10.008

A Series of Potent CREBBP Bromodomain Ligands Reveals an Induced‐Fit Pocket Stabilized by a Cation–π Interaction

Timothy P. C. Rooney, Panagis Filippakopoulos, Oleg Fedorov, Sarah Picaud, Wilian A. Cortopassi, Duncan A. Hay, Sarah Martin, Anthony Tumber, Catherine M. Rogers, Martin Philpott, Minghua Wang, Amber L. Thompson, Tom D. Heightman, David C. Pryde, Andrew Cook, Robert S. Paton, Susanne Müller, Stefan Knapp, Paul E. Brennan and Stuart J. Conway

Angew Chem Int Ed, 2014, 53, 6126
DOI: 10.1002/anie.201402750

Targeting bromodomains: epigenetic readers of lysine acetylation

Panagis Filippakopoulos and Stefan Knapp

Nat Rev Drug Discov, 2014, 13, 337
DOI: 10.1038/nrd4286

Development of methyl isoxazoleazepines as inhibitors of BET

Michael C. Hewitt, Yves Leblanc, Victor S. Gehling, Rishi G. Vaswani, Alexandre Côté, Christopher G. Nasveschuk, Alexander M. Taylor, Jean-Christophe Harmange, James E. Audia, Eneida Pardo, Rich Cummings, Shivangi Joshi, Peter Sandy, Jennifer A. Mertz, Robert J. Sims, Louise Bergeron, Barbara M. Bryant, Steve Bellon, Florence Poy, Hariharan Jayaram, Yong Tang and Brian K. Albrecht

Bioorganic & Medicinal Chemistry Letters, 2015, 25, 1842
DOI: 10.1016/j.bmcl.2015.03.045

BET inhibition as a new strategy for the treatment of gastric cancer

Raquel C. Montenegro, Peter G.K. Clark, Alison Howarth, Xiao Wan, Alessandro Ceroni, Paulina Siejka, Graciela A. Nunez-Alonso, Octovia Monteiro, Catherine Rogers, Vicki Gamble, Rommel Burbano, Paul E. Brennan, Cynthia Tallant, Daniel Ebner, Oleg Fedorov, Eric O’Neill, Stefan Knapp, Darren Dixon and Susanne Müller

Oncotarget, 2016, 7, 43997
DOI: 10.18632/oncotarget.9766

Drug Discovery Targeting Bromodomain-Containing Protein 4

Zhiqing Liu, Pingyuan Wang, Haiying Chen, Eric A. Wold, Bing Tian, Allan R. Brasier and Jia Zhou

J. Med. Chem., 2017, 60, 4533
DOI: 10.1021/acs.jmedchem.6b01761

Regioselective Nitration of N-Alkyl Anilines using tert-Butyl Nitrite under Mild Condition

Priyanka Chaudhary, Surabhi Gupta, Nalluchamy Muniyappan, Shahulhameed Sabiah and Jeyakumar Kandasamy

J. Org. Chem., 2019, 84, 104
DOI: 10.1021/acs.joc.8b02377

Development of Selective CBP/P300 Benzoxazepine Bromodomain Inhibitors

Tobias A. Popp, Cynthia Tallant, Catherine Rogers, Oleg Fedorov, Paul E. Brennan, Susanne Müller, Stefan Knapp and Franz Bracher

J. Med. Chem., 2016, 59, 8889
DOI: 10.1021/acs.jmedchem.6b00774

BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability

Laura E. Jennings, Matthias Schiedel, David S. Hewings, Sarah Picaud, Corentine M.C. Laurin, Paul A. Bruno, Joseph P. Bluck, Amy R. Scorah, Larissa See, Jessica K. Reynolds, Mustafa Moroglu, Ishna N. Mistry, Amy Hicks, Pavel Guzanov, James Clayton, Charles N.G. Evans, Giulia Stazi, Philip C. Biggin, Anna K. Mapp, Ester M. Hammond, Philip G. Humphreys, Panagis Filippakopoulos and Stuart J. Conway

Bioorganic & Medicinal Chemistry, 2018, 26, 2937
DOI: 10.1016/j.bmc.2018.05.003

Phenotypic Screening and Fragment-Based Approaches to the Discovery of Small-Molecule Bromodomain Ligands

Laura E Jennings, Angelina R Measures, Brian G Wilson and Stuart J Conway

Future Med. Chem., 2014, 6, 179
DOI: 10.4155/fmc.13.197

Discovery of novel CBP bromodomain inhibitors through TR-FRET-based high-throughput screening

Feng-cai Zhang, Zhong-ya Sun, Li-ping Liao, Yu Zuo, Dan Zhang, Jun Wang, Yan-tao Chen, Sen-hao Xiao, Hao Jiang, Tian Lu, Pan Xu, Li-yan Yue, Dao-hai Du, Hao Zhang, Chuan-peng Liu and Cheng Luo

Acta Pharmacol Sin, 2020, 41, 286
DOI: 10.1038/s41401-019-0256-2